36O First-in-human phase I study of a dual-conditionally active biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma

EpCAM (Epithelial Cell Adhesion Molecule) is a cell surface protein overexpressed by most adenocarcinomas. BA3182, a novel dual-conditionally binding EpCAM x CD3 TCE, is designed to selectively bind to both EpCAM and CD3 in the acidic tumor microenvironment (TME). In healthy tissues, binding of BA3182 to EpCAM is greatly reduced or eliminated, thus limiting on-target, off-tumor activity. Preclinical studies showed potent antitumor activity in colorectal and breast cancer models, with a >100-fold improvement in therapeutic index over non-conditionally binding EpCAM x CD3 TCEs.